Results 61 to 70 of about 21,933 (136)
Beta Thalassemia and Chronic Myeloid Leukemia: Dual Diagnosis Under the Microscope
International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 931-933, October 2026.
Paige Muir +3 more
wiley +1 more source
Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms
Cancer Science, Volume 117, Issue 4, Page 896-903, April 2026.In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley +1 more source
Research progress in animal models of dry eye disease: Types, mechanisms, and application prospects
Animal Models and Experimental Medicine, Volume 9, Issue 3, Page 462-485, March 2026.Pivotal multifactorial animal models for translational dry eye disease research. Abstract Dry eye disease (DED) is a prevalent and complex multifactorial ocular surface disorder, leading to significant visual discomfort and diminished quality of life.
Jinshen Liu +12 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 2, February 2026.ABSTRACT The aim of this case report is to introduce the reader to dermatofibrosarcoma protuberans (DFSP). In addition to the general characteristics of this rare skin tumor with possible metastatic potential, we also describe an atypical genetic finding that made our patient's case unique.
Jakub Bejbl +3 more
wiley +1 more source
Early imatinib mesylate-induced hepatotoxicity in chronic myelogenous leukaemia
, 2021 Imatinib mesylate is the first molecule of targeted therapy in chronic myelogenous leukaemia inhibiting constitutively activated BCR-ABL kinase. There are no long-term follow-up studies of large sample sizes to assess the toxicity of the use of imatinib ...
문영철 +5 more
core +1 more source
Cancer Reports, Volume 9, Issue 1, January 2026.ABSTRACT Background Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events.
Nandhini Gangadaran +9 more
wiley +1 more source
Genetic Analysis of Imatinib Resistance in CML: The Role of T315I and E255K
Advances in Hematology, Volume 2026, Issue 1, 2026.Background and Aims Imatinib mesylate is a small molecule inhibitor targeting the BCR‐ABL tyrosine kinase. However, some CML patients develop resistance to imatinib. This resistance is commonly associated with mutations in the kinase domain of BCR‐ABL, notably the prevalent T315I and E255K mutations.
Saba Yari +4 more
wiley +1 more source
Impact of Imatinib Therapy on Immunometabolism to Promote β‐Cell Survival in Diabetes
Journal of Diabetes, Volume 18, Issue 7, July 2026.
Sandeep Kumar, Reena Kumari
wiley +1 more source
International Journal of Endocrinology, Volume 2026, Issue 1, 2026.Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang +6 more
wiley +1 more source
XML Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
Iranian Journal of Blood and Cancer, 2016 Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML).
Abolghasem Allahyari +3 more
doaj